High-grade B-cell lymphomas with concurrent MYC and BCL2 and/or BCL6 rearrangement, also called double-hit and triple hit lymphoma (HGBCL-DH/TH), are recognized as a distinct entity according to the 2017 WHO classification. 1 Most HGBCL-DH/TH patients present with advanced stage and high-risk disease (according to the International Prognostic Index [IPI]). 2,3 Outcomes following R-CHOP-like are unsatisfactory, which led to wide-spread use of intensified firstline regimens. It is, however, still debatable whether this approach improves overall survival (OS). In order to get more insight into routine clinical practice and to obtain additional survival data, we performed a retrospective, multicenter, patient-level pooled analysis on HGBCL-DH/TH patients.Patients' data were collected from one academic database.Additionally, we systematically reviewed the literature from 2014 onwards. All studies on HGBCL-DH/TH patients with available individual patient data (IPD) were included. Altogether, data from 11 previously published retrospective trials were included. 4-14 Three of the authors provided IPD on request. We included patients with newly diagnosed HGBCL-DH/TH, in accordance to the 2017 WHO criteria, 1 that received rituximab-based induction in a curative approach. We further grouped patients into two cohorts based on applied treatment: The standard group (SG) included patients treated with R-CHOP-like; all other patients, including those with R-CHOP